| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04688931 Details | 2023-08-03 Interventional | 3 | 282 | Mitomycin Mitomycins Carcinoma Carcinoma, Tran… Non-Muscle Inva… Urinary Bladder… Bladder Cancer Urothelial Carc… Urothelial Carc… | Alternate approach pursued - | |||
| NCT04362293 Details | 2023-08-03 Interventional | 2 | - | Alemtuzumab Azathioprine Cyclophosphamid… Hydroxyurea MTOR Inhibitors Plerixafor Sirolimus Temsirolimus Thiotepa Anemia, Sickle … Sickle Cell Dis… | We are holding enrollment, due to some recent SAEs. - | |||
| NCT03024996 2016-001881-27 Details | 2023-08-03 Interventional | 3 | 778 | Atezolizumab Carcinoma Carcinoma, Rena… Renal Cell Carc… | The sponsor decided to terminate this study before the protocol-defined end-of-study, as
permitted per protocol. - | |||
| NCT02748564 Details | 2023-08-03 Interventional | 2 | 10 | Aldesleukin Interleukin-2 Pembrolizumab Melanoma Melanoma, Cutan… Skin Neoplasms Metastatic Mela… Stage III Mucos… Stage IIIA Skin… Stage IIIB Skin… Stage IIIC Skin… Stage IV Skin M… Stage IVA Mucos… Stage IVB Mucos… Stage IVC Mucos… | Study Complete - | |||
| NCT00707655 Details | 2023-08-03 Interventional | 1/2 | 8 | Zalutumumab Carcinoma Carcinoma, Squa… Head and Neck N… Head and Neck C… Squamous Cell C… | The decision is based on company re-evaluation of indications to be pursued within SCCHN All adverse events were collected during the 8 week treatment period and for 4 additional weeks. Serious adverse events were collected for the extended follow-up period of 2 years. | |||
| NCT00488605 Details | 2023-08-03 Interventional | 3 | 0 | Leucovorin Levoleucovorin Methotrexate Prednisone Vinblastine Histiocytosis Histiocytosis, … Leukemia | This is a duplicate record and the sponsor has registered the study. - | |||
| NCT05926206 Details | 2023-08-02 Interventional | 1/2 | 0 | Folfirinox Adenocarcinoma Metastatic Panc… | based some additional data, we have decided to hold off this trial for now and will not be
proceeding with this particular trial - | |||
| NCT05238207 Details | 2023-08-02 Interventional | 1 | 24 | Psyllium Hemochromatosis Hemosiderosis Hereditary Hemo… | Only Part A (single dosing) was conducted due to business considerations - | |||
| NCT03662074 Details | 2023-08-02 Interventional | 2 | 14 | Gemcitabine Nivolumab Lung Neoplasms Small Cell Lung… Stage IV Lung C… Stage IVA Lung … Stage IVB Lung … | After interim analysis decided not to move forward with continuing the trial. - | |||
| NCT04971187 Details | 2023-08-01 Interventional | 2 | 3 | Carboplatin Cisplatin Pemetrexed Carcinoma Carcinoma, Non-… Lung Neoplasms Locally Advance… Metastatic Lung… Stage III Lung … Stage IIIA Lung… Stage IIIB Lung… Stage IIIC Lung… Stage IV Lung C… Stage IVA Lung … Stage IVB Lung … Unresectable Lu… | PI Request The study was terminated early due to the drug company no longer producing the drug. | |||
| NCT04901299 Details | 2023-08-01 Interventional | 2 | 0 | Fulvestrant Neratinib Breast Neoplasm… ER Positive Bre… HER2-negative B… Invasive Breast… Metastatic Brea… PR-Positive Bre… Stage IV (Metas… | Team decision - | |||
| NCT04882072 Details | 2023-08-01 Interventional | 3 | 14 | Ustekinumab Aortic Arch Syn… Arteritis Takayasu Arteri… | Due to difficulties in enrollment and ongoing feasibility issues - | |||
| NCT03956056 Details | 2023-08-01 Interventional | 1 | 12 | Carboxymethylce… Poly I-C Poly ICLC Pancreatic Neop… Cancer of the P… Pancreas Cancer Pancreatic Canc… | Insufficient funding/staff - | |||
| NCT03277482 Details | 2023-08-01 Interventional | 1 | 16 | Durvalumab Tremelimumab Carcinoma Carcinoma, Ovar… Endometrial Neo… Ovarian Neoplas… Recurrence Uterine Cervica… Vaginal Neoplas… Vulvar Neoplasm… Metastatic Cerv… Metastatic Endo… Metastatic Ovar… Metastatic Vagi… Metastatic Vulv… Recurrent Cervi… Recurrent Endom… Recurrent Gynec… Recurrent Ovari… Recurrent Vagin… Recurrent Vulva… | Expansion cohort was not open - | |||
| NCT02844933 Details | 2023-08-01 Interventional | 2 | 7 | Cannabidiol Prader-Willi Sy… Syndrome | Insys Therapeutics filed Chapter 11 and terminated all studies. This study was prematurely terminated by the previous Sponsor (Insys Therapeutics Inc.). Only 7 participants were enrolled, and the planned number of participants was not achieved. | |||
| NCT02059265 Details | 2023-08-01 Interventional | 2 | 35 | Dasatinib Adenocarcinoma,… Carcinoma Cystadenocarcin… Recurrence Endometrial Cle… Ovarian Clear C… Recurrent Fallo… Recurrent Ovari… Recurrent Prima… Recurrent Uteri… | Interim monitoring - | |||
| NCT05177796 Details | 2023-07-28 Interventional | 2 | 0 | Albumin-Bound P… Antibodies Antibodies, Mon… Antineoplastic … Carboplatin Cyclophosphamid… Daunorubicin Doxorubicin Immunoglobulins Liposomal doxor… Paclitaxel Panitumumab Pembrolizumab Breast Neoplasm… Carcinoma Inflammatory Br… Anatomic Stage … Anatomic Stage … Anatomic Stage … Anatomic Stage … Anatomic Stage … Breast Inflamma… Invasive Breast… Prognostic Stag… Prognostic Stag… Prognostic Stag… Prognostic Stag… Prognostic Stag… Triple-Negative… | 0 participants recruited - | |||
| NCT04561180 Details | 2023-07-28 Interventional | 2 | 0 | Dexamethasone COVID-19 Pneumonia COVID-19 Pneumo… | No patients COVID-19 morbidity decreased. - | |||
| NCT02618577 2015-003997-33 Details | 2023-07-28 Interventional | 3 | 2608 | Edoxaban Atrial High Rat… | following a recommendation from the data safety and monitoring board due to safety concerns and
a tendency towards futility. - | |||
| NCT05961007 Details | 2023-07-27 Interventional | 1/2 | - | Aflibercept Edema Macular Degener… Macular Edema Wet Macular Deg… Diabetic Macula… Neovascular Age… | Company strategy adjustment - |